Login / Signup

Cognitive effects of cilostazol in Alzheimer's dementia patients with peripheral arterial occlusive disease: A case-control study.

Ching-Fang ChienLing-Chun HuangKuan-Ying LiYuan-Han Yang
Published in: Geriatrics & gerontology international (2023)
In AD patients with peripheral arterial occlusive disease who have received Food and Drug Administration-approved pharmacotherapy, cilostazol, as an antiplatelet, may help to preserve general cognitive function, with significant preservation in category fluency. Geriatr Gerontol Int 2023; 23: 194-199.
Keyphrases
  • drug administration
  • sickle cell disease
  • mild cognitive impairment
  • risk assessment